Ventyx Biosciences, Inc. (VTYX) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Needham Starts NeoVolta (NEOV) at Buy
- S&P 500 ends lower; chips tumble and Moderna rallies
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
August 15, 2022 4:05 PM EDTVTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial
Cash, cash equivalents and marketable securities of $258.4 million as of June 30, 2022, expected to support operations into the first half of 2024
Ventyx to host conference call and webcast today at 4:30 PM ET to discuss topline results from the Phase 1 trial of VTX958
ENCINITAS, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral... More
